Global drugmaker Novartis will spin off its generics and biosimilars company, Sandoz, to focus on “innovative medicines” as pharmaceutical companies selling generics struggle to compete with the high costs of brand name drugs.
Read the full post on Becker's Hospital Review - Healthcare News
